Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Objective and McKinley Scientific Announce a Strategic Co-Marketing Collaboration

Published: Friday, November 30, 2012
Last Updated: Thursday, November 29, 2012
Bookmark and Share
Co-marketing agreement designed to enable and expand key applications for delivery of high-performance LC-MS systems.

McKinley Scientific, LLC and New Objective, Inc. have announced that they have entered into a strategic co-marketing and development agreement designed to enable and expand key applications for delivery of high-performance LC-MS systems.

This includes the financing and support services for mass spectrometry provided by McKinley Scientific and New Objective's industry-recognized nanospray front-end technologies.

Together, the firms intend to co-market their products through industry publications and trade shows, and the development of distribution and services to deliver high-end MS solutions.

Paul Corcoran, President and CEO of McKinley Scientific commented that: "New Objective and McKinley Scientific have enjoyed a close relationship for many years. It was a natural progression for us to combine our collective strengths into a mutually beneficial relationship. Our combined customer focus will yield broader and more powerful solutions with expanded choices, adaptability, and education opportunities. We are very excited to support Dr. Valaskovic along with the wonderful products and people at New Objective."

Dr. Gary Valaskovic, the co-founder and President of New Objective adds: "I am very pleased to have strengthened and formalized the excellent, long standing relationship between New Objective and McKinley Scientific. Paul Corcoran and McKinley are an outstanding team of individuals dedicated to transforming the business of mass spectrometry and related technologies in the life science marketplace. The combination of New Objective¹s world class front-end hardware and consumables, with the outstanding finance, sales, and support structure of McKinley Scientific is a winning combination for the customer, one that will enable the development of new markets for both organizations."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Making It Personal
Cancer vaccine linked to increased immune response against leukemia cells.
Gene Therapy Maintains Clotting Factor for Hemophilia Patients
Following a single gene therapy dose, the highest levels of an essential blood clotting factor IX were observed in hemophilia B patients.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!